Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist

Research output: Contribution to journalArticle

Abstract

Cancer cachexia is a multi-organ, multifactorial and often irreversible syndrome affecting many patients with cancer. Cancer cachexia is invariably associated with weight loss, mainly from loss of skeletal muscle and body fat, conditioning a reduced quality of life due to asthenia, anorexia, anaemia and fatigue. Treatment options for treating cancer cachexia are limited. The approach is multimodal and may include: treatment of secondary gastrointestinal symptoms, nutritional treatments, drug, and non-drug treatments. Nutritional counselling and physical training may be beneficial in delaying or preventing the development of anorexia-cachexia. However, these interventions are limited in their effect, and no definitive pharmacological treatment is available to address the relevant components of the syndrome. Anamorelin is a first-in-class, orally active ghrelin receptor agonist that binds and stimulates the growth hormone secretagogue receptor centrally, thereby mimicking the appetite-enhancing and anabolic effects of ghrelin. It represents a new class of drug and an additional treatment option for this patient group, whose therapeutic options are currently limited. In this review we examine the mechanisms of anamorelin by which it contrasts catabolic states, its role in regulation of metabolism and energy homeostasis, the data of recent trials in the setting of cancer cachexia and its safety profile.

Original languageEnglish
Article number1433
Pages (from-to)793-797
Number of pages5
JournalCancer Treatment Reviews
Volume41
Issue number9
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • Anamorelin
  • Cancer cachexia
  • Ghrelin receptor

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Fingerprint Dive into the research topics of 'Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist'. Together they form a unique fingerprint.

  • Cite this